

New Release April 2024


Clinically Aligned Pretreated PDX Models

Our clinically aligned pretreated PDX models are the most translatable PDX models available, closing the gap between preclinical and clinical results. These models reflect today's patient populations and cancer treatments, with detailed patient and treatment histories available for each. Our collection includes models from patients who received multiple lines of treatment and features models of metastatic disease states collected from various biopsy sites, clinically relevant mutations, as well as matching longitudinal models. Evaluate your next generation therapeutics with the most clinically relevant models reflecting the patient population and cancer treatments of today.


Clinically Aligned Pretreated PDX Collection Key Facts

- Over 100 clinically aligned pretreated PDX models covering many cancer types derived from patients of western origin with different drug treatments, including documented multiple lines of treatment.
- Treatments include immune checkpoint inhibitors, 3rd generation EGFRi, PARPi, KRASi, CDK4/6i, and BTKi.
- 50+ pretreated PDX models representing advanced, metastatic disease with samples collected from various biopsy sites.

Clinically Aligned Pretreated PDX Models by Indication



Clinically Aligned Pretreated PDX Models by Treatment



Newly Added Clinically Aligned Pretreated PDX Models April 2024

Our newest cohort of clinically aligned pretreated PDX models, listed in the table below, represent patients who received multiple lines of treatment and include metastatic disease states collected from various biopsy sites and clinically relevant mutations. Use our searchable online PDX database ([HuBase™](#)) to view additional details for these models, including available validation (SoC) data, genomic, and proteomic data to help you find the best models for your research needs.

Model ID	Cancer type	Metastatic pathology diagnosis	Biopsy site	Treatment history	Comments
BR9552	Breast Cancer	Yes	Left Axillary Lymph Node	1st Abraxane + Tecentriq, 2nd Carboplatin + Gemzar, 3rd Doxil, 4th Investigational, 5th Investigational	Slight Ulceration, From same patient as BR9655
BR9671	Breast Cancer	Yes	Right Supraclavicular Lymph Node	1st ddAC-T, 2nd Tamoxifen, 3rd Capecitabine, 4th Everolimus + Exemestrane, 5th Olaparib, 6th Eribulin, 7th Gemcitabine	Slight Ulceration
BR9690	Breast cancer	Yes	Left chest wall mass	1st Doxorubicin + Cyclophosphamide, 2nd Paclitaxel + Carboplatin, 3rd Capecitabine, 4th Kinase inhibitor of RET, TAM, VEGFR2, KIT + Nivolumab, 5th Anti-Mucin 1 - EGFR bispecific ADC, 6th Sacituzumab govitecan	Slight Ulceration
CR9520	Colorectal Cancer	Yes	Parasacral Mass	1st Fluorouracil + Cisplatin, 2nd Carboplatin + Paclitaxel, 3rd Fluorouracil + Mitomycin + Radiotherapy, 4th Nivolumab, 5th Fluorouracil + Oxaliplatin	Slight Ulceration, From same patient as CR9551
CR9553	Colorectal Cancer	Yes	Perihepatic Soft tissue Lesion	1st FOLFOX, 2nd FOLFIRI + Bevacizumab, 3rd FOLFOX + Bevacizumab	Slight Ulceration
CR9663	Colorectal Cancer	Yes	Perirectal mass	1st FOLFOX, 2nd FOLFIRI + Avastin, 3rd Keytruda	N/A
CR9678	Colorectal Cancer	Yes	Liver	1st FOLFOX+Panitumumab 2nd FOLFIRI+Bevacizumab, 3rd FOLFOX, 4th Investigational change to Peptide-Drug Conjugate	N/A
CR9684	Colorectal Cancer	Yes	Liver	1st FOLFOX + Bevacizumab, 2nd XELOX + Avastin, 3rd FOLFIRI + Avastin	Slight Ulceration
CR9689	Colorectal Cancer	Yes	Liver	1st 5-FU	N/A
ES9554	Esophageal Cancer	Yes	Liver	1st Cisplatin + Fluorouracil + Trastuzumab, 2nd Cyramza + Taxol	Slight Ulceration
LU9901	Lung Cancer	N/A	Lung	"Afatinib (2016-01-12~2017-01-04) Pemetrexed/Cisplatin (2016-02-15~2016-03-10) Whole brain radiotherapy (2017-06-21 ~ 2017-07-06) tissue collection: 2017-06-26"	Afatinib resistant
LU9908	Lung Cancer	N/A	Lung	"M7824 (2019-05-03~2019-10-30) Tepotinib (2020-01-06~2020-03-11) Pemetrexed/Cisplatin (~2020-04-01) Pembrolizumab + Vinorelbine + Carboplatin (2020-07-01~) tissue collection: 2020-04-27"	Slight Ulceration
OV9534	Ovarian Cancer	Yes	Right Perihepatic Mass	1st Gemcitabine + Carboplatin + Bevacizumab, 2nd Avelumab, 3rd Doxorubicin, 4th Bevacizumab, 5th Investigational, 6th Investigational + Pembrolizumab	Slow growth rate, Slight Ulceration



Scan to view



Full length
Pretreated factsheet



The GEN webinar on
Pretreated PDX

Get in touch



Sales

US: +1 858 622 2900
UK: +44 870 242 2900

busdev@crownbio.com
www.crownbio.com



Science

consultation@crownbio.com

